MDO and Insurer Questions About AI in Clinics

AI use may become relevant during insurer renewal, PMI due diligence, an MDO query, a complaint or a clinical incident. The clinic may be asked practical questions: what tool was used, who approved it, whether the clinician reviewed the output, whether the patient was informed and what governance process existed. ELSA AI does not provide insurer coverage advice or MDO indemnity advice. We help clinics organise the evidence likely to be relevant to those discussions.

Who this is for

  • Clinic owners and boards
  • GP partners
  • Practice managers
  • Clinicians using AI-assisted documentation
  • Governance leads preparing renewal or disclosure materials

Questions that may arise

Checklist

  • Which AI tools are used in documentation, transcription, triage or clinical workflows?
  • Does patient data enter the tool?
  • Who approved the tool?
  • Was a DPIA completed or reviewed?
  • Is vendor evidence available?
  • Are clinicians required to review AI-generated outputs?
  • Are patients informed where AI records, transcribes or supports documentation?
  • Does the incident process cover AI-related errors?
  • Has material AI use been reviewed with advisers where relevant?

Common evidence gaps

Checklist

  • AI use not recorded
  • Scribe live without central evidence file
  • No human-review protocol
  • No patient transparency wording
  • No AI incident route
  • No disclosure-readiness note
  • No board-approved AI position

Careful wording: use

  • may affect indemnity support
  • should be clarified directly with the MDO or insurer
  • disclosure-readiness evidence
  • final decision remains with provider

Avoid

  • cover void
  • claim will be rejected
  • insurer will not pay
  • MDO will refuse support

What ELSA AI can help produce

The Diagnostic includes disclosure-readiness indicators aligned to common renewal and incident questions.

Outputs include

  • MDO, PMI and Insurer Disclosure Readiness Note
  • AI Tool and Use Case Inventory
  • Human oversight evidence review
  • Incident process gap indicators
  • Vendor Data Position and Evidence Tracker
  • 30-Day Priority Action Plan

The issue is not simply that AI tools exist. The issue is having no documented governance position when someone asks how that AI use is controlled. Clinical AI Exposure Diagnostic™ page explains scope, timeline and fees.

Advisory governance support only. Not legal advice, DPIA sign-off, CQC certification, ICO approval, insurer coverage advice, MDO indemnity advice or clinical safety case sign-off. Final decisions remain with the clinic’s accountable officers and advisers.

Need this evidence mapped for your clinic?

The Clinical AI Exposure Diagnostic™ gives clinic leadership a board-ready view of AI use, patient-data exposure, evidence gaps and priority actions in four working days from completed intake.

Book a confidential 20-minute discovery callView Diagnostic deliverables

Related guides